Loading...
•
Jun 30, 2024
Vera Q2 2024 Earnings Report
Reported business highlights and financial results for the second quarter ended June 30, 2024.
Key Takeaways
Vera Therapeutics reported a net loss of $33.7 million, or a net loss per diluted share of $0.62 for the quarter ended June 30, 2024. The company's cash, cash equivalents, and marketable securities totaled $384.4 million as of June 30, 2024.
Received FDA Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN).
Presented data from Phase 2b ORIGIN study at ERA24 Congress showing atacicept stabilized kidney function through 72 weeks and led to rapid reductions in hematuria.
Topline 96-week data from Phase 2b ORIGIN study expected in Q4 2024.
On track to complete enrollment in pivotal Phase 3 ORIGIN 3 trial for primary endpoint in Q3 2024; topline data expected in Q2 2025.
Vera
Vera
Forward Guidance
The company plans to present topline 96-week data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in the fourth quarter of 2024 and expects to complete enrollment in the pivotal Phase 3 ORIGIN 3 trial in the third quarter of 2024, with topline data expected in Q2 2025.